Table 1.
Laboratory data of chronic renal failure patients with COVID-19 before and after dialysis.
| Laboratory test | Case1 |
Case2 |
||
|---|---|---|---|---|
| Before CVVHDF |
After CVVHDF | Before CVVHDF | After CVVHDF | |
| Total white cell count (x109 /L NR 3.5–9.5) |
8.59 | 7.90 | 15.49 | 5.68 |
| Lymphocyte count (x109/L NR 1.10–3.20) |
0.92 | 0.74 | 1.01 | 0.58 |
| Hemoglobin (g/L NR 130–175) |
85 | 92 | 35 | 83 |
| PCT (ng/mL NR 0.02–0.05) |
0.8 | 0.58 | 1.59 | 1.40 |
| ALT (U/L NR ≤ 41) | 57 | 6 | 11 | 15 |
| AST (U/L NR ≤ 40) | 51 | 23 | 16 | 16 |
| Creatinine (umol/L NR 59–104) |
776 | 245 | 1175 | 558 |
| Urea (mmol/L NR 3.6–9.5) |
26.93 | 20.70 | 33.71 | 24.3 |
| eGFR (ml/min/1.73 m2 NR <90) |
5.2 | 20.8 | 3.1 | 7.6 |
| Hypersensitive cardiac troponin (pg/ml NR <34.2) |
85.4 | 67.8 | 24.3 | 30.4 |
| NT-proBNP (pg/ml NR (486) |
>70000 | 22,490 | 11,218 | 2481 |
| IL-6 (pg/ml NR <7) | 88 | 41.06 | 124.9 | 15.07 |
| IL-10 (pg/ml NR <9.1) | 36.7 | 6.3 | <5.0 | 10.8 |
| IL-2R (pg/ml NR 223–710) |
2575 | 2091 | 1622 | 1200 |
| TNF-α(pg/ml NR <8.1) | 28.2 | 28.6 | 12.7 | 16.7 |
Note: CVVHDF, continuous venovenous hemodiafiltration; PCT, procalcitonin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NT-proBNP, Amino terminal brain natriuretic peptide precursor; IL, Interleukin; TNF-α,Tumor necrosis factor-α.